In addition to improving GCV activation, combining the HSV-tk/GCV system with other strategies, such as cytokine therapy, has been demonstrated in several tumor systems to be more effective than using a single treatment [10], [11], [12], [13]. This evidence concerns the gene TKT and neoplasm.